【诺和诺德新药减重效果不及预期，美股盘前大跌】金十数据12月20日讯，诺和诺德周五表示，其实验性下一代减肥药CagriSema在后期试验中帮助超重患者减重22.7%，低于预期的25%，该消息导致公司股价大幅下跌。这一低于预期的数据对诺和诺德来说是一个打击，该公司原本希望CagriSema能成为比礼来的减肥药Zepbound更强大的产品，以接替其上一代减肥药Wegovy。投资者和分析师一直热切期待这些数据，以检验诺和诺德在激烈的抗肥胖市场竞争中是否拥有一个强大的后续产品来接替Wegovy。在周五公布结果后，诺和诺德股价在美股盘前大跌22%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.